Low levels of steroid-metabolizing hepatic enzyme (cytochrome P450 3A) activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose

Journal of Orthopaedic Science

Volumn 14, Issue 6, 2009, Pages 794-800

  Tokuhara, Yoshio ^a   Wakitani, Shigeyuki ^b   Oda, Yutaka ^b   Kaneshiro, Yasunori ^b   Masada, Toshiaki ^b   Kim, Mitsunari ^a   Kadoya, Yoshinori ^a   Azuma, Takashi ^a   Takaoka, Kunio ^a  

^a Hanwa Joint Reconstruction Center Hospital   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ITRACONAZOLE; LIVER ENZYME; METHYLPREDNISOLONE; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; FEMUR HEAD NECROSIS; HISTOLOGY; LOW DRUG DOSE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; STEROID INDUCED OSTEONECROSIS OF THE FEMORAL HEAD;

EID: 72949099313     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-009-1400-5     Document Type: Article

References (25)

1. M.A. Mont D.S. Hungerford 1995 Non-traumatic avascular necrosis of the femoral head J Bone Joint Surg Am 77 3 459 474 1:STN:280:DyaK2M7pslOjsw%3D%3D 7890797
2. Y. Hirota T. Hirohata K. Fukuda M. Mori H. Yanagawa Y. Ohno Y. Sugioka 1993 Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head Am J Epidemiol 137 5 530 538 1:STN:280:DyaK3s3itVKlsA%3D%3D 8465804
3. T.M. Zizic C. Marcoux D.S. Hungerford J.V. Dansereau M.B. Stevens 1985 Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus Am J Med 79 5 596 604 10.1016/0002-9343(85)90057-9 1:STN:280:DyaL28%2FkslyksA%3D%3D 4061472 (Pubitemid 16191213)
4. A.A. Kalla I.D. Learmonth P. Klemp 1986 Early treatment of avascular necrosis in systemic lupus erythematosus Ann Rheum Dis 45 8 649 652 10.1136/ard.45.8.649 1:STN:280:DyaL283psVOrsg%3D%3D 3740994
5. T. Yamamoto T. Irisa Y. Sugioka K. Sueishi 1997 Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroidinduced osteonecrosis in rabbits Arthritis Rheum 40 11 2055 2064 10.1002/art.1780401119 1:CAS:528:DyaK2sXns1ygsbo%3D 9365096 (Pubitemid 27494667)
6. K. Miyanishi T. Yamamoto T. Irisa A. Yamashita S. Jingushi Y. Noguchi Y. Iwamoto 2002 Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis Bone (NY) 30 1 185 190 1:STN:280:DC%2BD38%2FpvVCjtg%3D%3D
7. G. Motomura T. Yamamoto K. Miyanishi S. Jingushi Y. Iwamoto 2004 Combined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits Arthritis Rheum 50 10 3387 3391 10.1002/art.20517 1:CAS:528:DC%2BD2cXpvFait78%3D 15476219 (Pubitemid 39372017)
8. E.S. Weiner M. Abeles 1989 Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation J Rheumatol 16 5 604 608 1:STN:280:DyaL1MzivV2jtw%3D%3D 2666654
9. J.H. Schellens P.A. Soons D.D. Breimer 1988 Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects Biochem Pharmacol 37 13 2507 2510 10.1016/0006-2952(88)90238-9 1:CAS:528: DyaL1cXks1KgsLs%3D 3390213 (Pubitemid 18162359)
10. Y.S. Lin G.F. Lockwood M.A. Graham W.R. Brian C.M. Loi M.R. Dobrinska, et al. 2001 In-vivo phenotyping for CYP3A by a singlepoint determination of midazolam plasma concentration Pharmacogenetics 11 9 781 791 10.1097/00008571-200112000-00006 1:CAS:528:DC%2BD38XnsFKqsrY%3D 11740342 (Pubitemid 33151513)
11. K.E. Thummel D.D. Shen T.D. Podoll K.L. Kunze W.F. Trager C.E. Bacchi, et al. 1994 Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients J Pharmacol Exp Ther 271 1 557 566 1:CAS:528:DyaK2MXhvVyqu7Y%3D 7965756
12. T. Varis K.M. Kaukonen K.T. Kivistö P.J. Neuvonen 1998 Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole Clin Pharmacol Ther 64 4 363 368 10.1016/S0009-9236(98)90066-2 1:STN:280:DyaK1M%2FhsVGhtA%3D%3D 9797792 (Pubitemid 28473761)
13. T. Varis K.T. Kivisto J.T. Backman P.J. Neuvonen 2000 The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect Clin Pharmacol Ther 68 5 487 494 10.1067/mcp.2000.110772 1:CAS:528:DC%2BD3cXovVeruro%3D 11103751 (Pubitemid 30953868)
14. T. Varis K.T. Kivisto P.J. Neuvonen 2000 The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone Eur J Clin Pharmacol 56 1 57 60 10.1007/s002280050720 1:CAS:528:DC%2BD3cXisVOjsL4%3D 10853878
15. Y. Kaneshiro Y. Oda K. Iwakiri T. Masada H. Iwaki Y. Hirota, et al. 2006 Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis Clin Pharmacol Ther 80 4 396 402 10.1016/j.clpt.2006.07.004 1:CAS:528:DC%2BD28XhtVWqurjJ 17015057 (Pubitemid 44479755)
16. T. Masada K. Iwakiri Y. Oda Y. Kaneshiro H. Iwaki Y. Ohashi K. Takaoka 2008 Inverse correlation of hepatic cytochrome P450 3A activity to the risk for glucocorticoid-induced osteonecrosis in a rabbit model J Orthop Res 26 1 91 95 10.1002/jor.20484 1:CAS:528:DC%2BD1cXhtleksbk%3D 17787012
17. C.R. Jones F.P. Guengerich J.M. Rice R.A. Lubet 1992 Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates Pharmacogenetics 2 4 160 172 10.1097/00008571-199208000-00003 1:CAS:528:DyaK3sXlsFWmu7c%3D 1306117
18. T.A. Kocarek E.G. Schuetz S.C. Strom R.A. Fisher P.S. Guzelian 1995 Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes Drug Metab Dispos 23 3 415 421 1:CAS:528:DyaK2MXksVehs78%3D 7628309
19. N. Isoherranen K.L. Kunze K.E. Allen W.L. Nelson K.E. Thummel 2004 Role of itraconazole metabolites in CYP3A4 inhibition Drug Metab Dispos 32 10 1121 131 10.1124/dmd.104.000315 1:CAS:528:DC%2BD2cXot12ltbo%3D 15242978 (Pubitemid 39287586)
20. T. Osanai T. Ohkubo N. Yasui T. Kondo S. Kaneko 2004 Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam Br J Clin Pharmacol 58 5 476 481 10.1111/j.1365-2125.2004.02208.x 1:CAS:528:DC%2BD2cXhtFahur7O 15521894 (Pubitemid 39540450)
21. J.T. Backman K.T. Kivisto K.T. Olkkola P.J. Neuvonen 1998 The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur J Clin Pharmacol 54 1 53 58 10.1007/s002280050420 1:CAS:528:DyaK1cXhvFCqt7k%3D 9591931 (Pubitemid 28189400)
22. K. Miyanishi T. Yamamoto T. Irisa A. Yamashita S. Jingushi Y. Noguchi Y. Iwamoto 2001 A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits Rheumatology (Oxf) 40 2 196 201 10.1093/rheumatology/40.2.196 1:CAS:528:DC%2BD3MXisFOlt7o%3D
23. D.E. Fisher W.H. Bickel K.E. Holley R.D. Ellefson 1972 Corticosteroidinduced aseptic necrosis: experimental study Clin Orthop Relat Res 84 200 206 10.1097/00003086-197205000-00033 1:STN:280:DyaE383gsVyqtA%3D%3D 5032843
24. D.E. Fisher 1978 The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results Clin Orthop Relat Res 130 68 80 639408
25. J.P. Jones Jr 1993 Fat embolism, intravascular coagulation, and osteonecrosis Clin Orthop Relat Res 292 294 308 8519124